AbbVie: 4 Hidden Keys Investors Must Know To Judge ImmunoGen Acquisition


  • AbbVie has agreed to acquire ImmunoGen for $10 billion, nearly double its previous trading price.
  • The acquisition provides AbbVie with a commercial-stage company and a flagship drug that generated $105 million in sales in Q3.
  • Let’s look at this massive acquisition’s “behind the curtain” benefits.
Making money

Aslan Alphan/iStock via Getty Images

Do you wonder why companies are willing to pay what appears to be a hefty premium for other companies? If so, take a look at the four points below.

What happened?

In the biggest blockbuster acquisition since acquiring Allergen for

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ABBV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Investors' goals, financial situations, timelines, and risk tolerances vary widely. The stocks mentioned may not be suitable for all. As such, the article is not meant to suggest action on the reader's part. Each investor should consider their unique situation and perform their own due diligence.

The author is short the following option: ABBV MAR 2024 $160 CALL

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Leave a Reply

Your email address will not be published. Required fields are marked *